SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations

In patients with acute myeloid leukemia (AML), 10% to 30% with the normal karyotype express mutations in regulators of DNA methylation, such as TET2 or DNMT3A, in conjunction with activating mutation in the receptor tyrosine kinase FLT3. These patients have a poor prognosis because they do not respo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Invest
Hlavní autoři: Pandey, Ruchi, Ramdas, Baskar, Wan, Changlin, Sandusky, George, Mohseni, Morvarid, Zhang, Chi, Kapur, Reuben
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2019
Témata:
Concise Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877323/
https://ncbi.nlm.nih.gov/pubmed/31682240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI130520
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky